Lessons Learned From the Result of the Symplicity HTN-3 Trial: Industry’s View - Sandeep Brar, MD

↳ This is a section part of Moment: CRT 2015 Technology & Innovation - Session III: Best Evaluation for Renal Denervation - Same or Different in Japan and USA?

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Lessons Learned From the Result of the Symplicity HTN-3 Trial: Industry’s View presented by Sandeep Brar, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Clinical Trial Investigators
  • Medical Device Professionals

Session Name: Session III: Best Evaluation for Renal Denervation - Same or Different in Japan and USA?

Track: Technology & Innovation

Learning Objectives

  • Updates on regulatory harmonisation and clinical trial design in the US & Japan

Other Components in this Moment

Overview
Lessons Learned From the Result of the Symplicity HTN-3 Trial: Industry’s View - Sandeep Brar, MD
Points to Consider in the Device Development for Renal Denervation: Japan Academia’s View - Takafumi Ueno, MD, PhD
Points to Consider in the International Device Evaluation for Renal Denervation: JP Regulator’s View - Kohei Ohtsuki
Loading Simple Education